Innate Pharma (IPHA) News Today $1.76 0.00 (0.00%) Closing price 01/29/2025 03:59 PM EasternExtended Trading$1.74 -0.02 (-1.14%) As of 08:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Innate Pharma S.A. (NASDAQ:IPHA) Short Interest UpdateInnate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 101,000 shares, a drop of 88.9% from the December 31st total of 909,800 shares. Based on an average trading volume of 467,300 shares, the short-interest ratio is presently 0.2 days.January 28 at 11:16 AM | marketbeat.comInnate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid TumorsJanuary 27 at 1:00 AM | businesswire.comInnate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New YorkJanuary 21, 2025 | businesswire.comCiti Keeps Their Buy Rating on Innate Pharma (IPHA)January 20, 2025 | markets.businessinsider.comInnate Pharma's (IPHA) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $11.50 price objective on shares of Innate Pharma in a research note on Friday.January 17, 2025 | marketbeat.comInnate Pharma S.A. (NASDAQ:IPHA) Short Interest Down 88.9% in DecemberInnate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the target of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 101,000 shares, a decline of 88.9% from the December 15th total of 909,800 shares. Based on an average daily volume of 467,300 shares, the short-interest ratio is currently 0.2 days.January 13, 2025 | marketbeat.comInnate Pharma Announces Transformative Strategy to Accelerate GrowthJanuary 10, 2025 | businesswire.comInnate Pharma S.A. (NASDAQ:IPHA) Short Interest Up 1,344.1% in DecemberInnate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 909,800 shares, a growth of 1,344.1% from the November 30th total of 63,000 shares. Based on an average daily trading volume, of 461,600 shares, the days-to-cover ratio is presently 2.0 days.December 26, 2024 | marketbeat.comInnate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 20, 2024 | businesswire.comInnate Pharma (NASDAQ:IPHA) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $11.50 price target on shares of Innate Pharma in a research note on Monday.December 9, 2024 | marketbeat.comInnate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell LymphomaDecember 9, 2024 | businesswire.comInnate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular LymphomaDecember 6, 2024 | businesswire.comInnate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024December 3, 2024 | businesswire.comInnate Pharma: Looking Like A Company We'll Regret IgnoringNovember 25, 2024 | seekingalpha.comInnate Pharma Releases Its 2025 Financial CalendarNovember 20, 2024 | businesswire.comInnate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501November 19, 2024 | businesswire.comInnate Pharma S.A. (NASDAQ:IPHA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comInnate Pharma S.A. (IPHA) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comInnate Pharma Reports Third Quarter 2024 Business Update and Financial ResultsNovember 13, 2024 | businesswire.comInnate Pharma (NASDAQ:IPHA) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $11.50 target price on shares of Innate Pharma in a research note on Tuesday.November 12, 2024 | marketbeat.comInnate Pharma (IPHA) Set to Announce Quarterly Earnings on WednesdayInnate Pharma (NASDAQ:IPHA) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports.November 8, 2024 | marketbeat.comInnate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024November 8, 2024 | businesswire.comInnate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business UpdatesNovember 7, 2024 | businesswire.comInnate Pharma Announces Its Participation in Upcoming Investor ConferencesOctober 29, 2024 | businesswire.comInnate Pharma S.A. (NASDAQ:IPHA) Sees Large Growth in Short InterestInnate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 71,800 shares, a growth of 20.3% from the September 15th total of 59,700 shares. Based on an average daily volume of 7,200 shares, the short-interest ratio is presently 10.0 days.October 14, 2024 | marketbeat.comInnate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive BoardOctober 14, 2024 | businesswire.comLeerink Partners Reaffirms Their Buy Rating on Innate Pharma (IPHA)October 9, 2024 | markets.businessinsider.comInnate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024September 30, 2024 | businesswire.comInnate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid TumorsSeptember 23, 2024 | businesswire.comInnate Pharma (NASDAQ:IPHA) Upgraded at Evercore ISIEvercore ISI raised shares of Innate Pharma to a "strong-buy" rating in a research note on Monday.September 18, 2024 | marketbeat.comHold Rating on Innate Pharma SA Amid FDA Discussions and Strategic UncertaintiesSeptember 13, 2024 | markets.businessinsider.comInnate Pharma (NASDAQ:IPHA) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $11.50 price target on shares of Innate Pharma in a research note on Friday.September 13, 2024 | marketbeat.comInnate Pharma (IPHA) Set to Announce Quarterly Earnings on ThursdayInnate Pharma (NASDAQ:IPHA) will be releasing earnings before the market opens on Thursday, September 12, Zacks reports.September 5, 2024 | marketbeat.comInnate Pharma SA: Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business UpdateSeptember 5, 2024 | finanznachrichten.deInnate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | businesswire.comShort Interest in Innate Pharma S.A. (NASDAQ:IPHA) Declines By 11.5%Innate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the target of a significant drop in short interest in July. As of July 31st, there was short interest totalling 64,500 shares, a drop of 11.5% from the July 15th total of 72,900 shares. Based on an average daily trading volume, of 8,300 shares, the days-to-cover ratio is presently 7.8 days.August 19, 2024 | marketbeat.comInnate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 TrialJune 17, 2024 | businesswire.comInnate Pharma (NASDAQ:IPHA) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $11.50 price target on shares of Innate Pharma in a report on Wednesday.June 12, 2024 | marketbeat.comInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis FungoidesJune 4, 2024 | businesswire.comInnate Pharma Announces Its Participation in Upcoming Investor ConferencesMay 28, 2024 | businesswire.comInnate Pharma Highlights Abstracts Selected for ASCO 2024 Annual MeetingMay 24, 2024 | businesswire.comOutcome of Innate Pharma's 2024 Annual General MeetingMay 23, 2024 | businesswire.comInnate Pharma: Clarification Regarding SAR443579 DesignationMay 21, 2024 | businesswire.comInnate Pharma Buy Rating Affirmed Amid Robust Pipeline and Financial StabilityMay 16, 2024 | markets.businessinsider.comInnate Pharma Highlights Abstracts Selected for EHA 2024 CongressMay 15, 2024 | businesswire.comInnate Pharma Reports First Quarter 2024 Business Update and Financial ResultsMay 14, 2024 | finance.yahoo.comInnate Pharma Reports First Quarter 2024 Business Update and Financial ResultsMay 14, 2024 | businesswire.comInnate Pharma (IPHA) Scheduled to Post Quarterly Earnings on TuesdayInnate Pharma (NASDAQ:IPHA) will be releasing earnings before the market opens on Tuesday, May 14, Zacks reports.May 8, 2024 | marketbeat.comInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business UpdateMay 7, 2024 | businesswire.comInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer PatientsApril 15, 2024 | businesswire.com Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address IPHA Media Mentions By Week IPHA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPHA News Sentiment▼1.190.76▲Average Medical News Sentiment IPHA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPHA Articles This Week▼41▲IPHA Articles Average Week Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AUTL News CGEM News HUMA News STOK News ERAS News ANAB News XERS News MNMD News RAPP News AKBA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IPHA) was last updated on 1/30/2025 by MarketBeat.com Staff From Our Partners#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredHot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapyA revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
